A phase I, open label study to assess the safety and tolerability of ZD6474 (Zactima) [vandetanib] in combination with vinorelbine (Navelbine) or gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (stage IIIB-IV) non small cell lung cancer.
Latest Information Update: 02 Sep 2016
At a glance
- Drugs Vandetanib (Primary) ; Cisplatin; Gemcitabine; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genzyme Corporation
- 17 Dec 2007 Status change from in progress to completed.
- 04 Aug 2007 New trial record.